Media Kit
Media inquiries
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com
About Xenon
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
Our lead molecule, azetukalner, is a novel, potent, Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). We are also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. We have offices in Vancouver, British Columbia, and Boston, Massachusetts.
Recent news
Visit our social channels to learn more about Xenon
Downloadable resources
These downloadable files are available for use by professional journalists.
Copyright © 2026 Xenon Pharmaceuticals Inc. — All materials and resources provided on this site by Xenon Pharmaceuticals Inc (the “Media Kit”) are protected by copyright and other intellectual property laws. The Media Kit provided on this website is intended for informational purposes only. Unauthorized use, reproduction, or distribution of any of these materials for commercial purposes is strictly prohibited and may result in legal consequences. By downloading any content from this Media Kit, you agree to use it solely for non-commercial purposes and in accordance with the terms outlined herein.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
To request permission to use Media Kit content for any purposes other than the ones expressly authorized above, please contact media@xenon-pharma.com.
Xenon corporate logo
Download LogoDisease burden infographic
Download the Unmet Need in Epilepsy InfographicLeadership headshots
Our science
